Skip to content

Prospective randomized controlled study of Qufeng Bushen Huoluo recipe in the treatment of hematuria in IgA Nephropathy

Clinical study of Qufeng Bushen Huoluo recipe in the treatment of hematuria in IgA Nephropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066983
Enrollment
Unknown
Registered
2022-12-22
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Experimental observation group:Losartan potassium tablets and traditional Chinese medicine Qufeng Bushen Huoluo recipe
Control group:Losartan potassium tablets

Sponsors

Jiujiang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.The patients were diagnosed as primary IgA nephropathy by renal biopsy and the syndrome differentiation was wind heat kidney deficiency. 2.Patients aged between 18 and 70. 3.Microscopic hematuria or gross hematuria, 24-hour proteinuria < 1g, serum creatinine less than 133umol/L. 4.Patients who did not use hormones or immunosuppressants within one month. 5.Patients who sign informed consent and are willing to cooperate with the completion of the trial.

Exclusion criteria

Exclusion criteria: 1. People preparing for pregnancy, pregnancy and lactation. 2. Participate in other experimental researchers. 3. Complicated with malignant tumors and other serious diseases of the system. 4. Clinical complications may cause secondary IgA deposition of systemic diseases, such as Henoch-Schonlein purpura nephritis, systemic lupus erythematosus, celiac disease, human immunodeficiency virus and so on.

Design outcomes

Primary

MeasureTime frame
serum creatinine;estimated glomerular filtration rate;Uric acid;plasma albumin;serum IgA;Complement 3;24-hour urine protein;Urine routine;Urinary red blood cell count;Urinary albumin creatinine ratio;

Secondary

MeasureTime frame
Blood lipids;Fibrinogen;

Countries

China

Contacts

Public ContactXuefei Lin

Jiujiang Hospital of Traditional Chinese Medicine

linxuefei.040@163.com+86 15279245881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026